Epigenetics as a Therapeutic Target in Breast Cancer

[1]  C. Zahnow,et al.  Abstract 4666: A phase 2 study investigating the safety, efficacy and surrogate biomarkers of response of 5-azacitidine (5-AZA) andentinostat (MS-275) in patients with triple-negative advanced breast cancer. , 2013 .

[2]  R. Wahl,et al.  Early change in 18-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) to predict response to preoperative systemic therapy (PST) in HER2-negative primary operable breast cancer: Translational breast cancer research consortium (TBCRC008). , 2012 .

[3]  C. Bloomfield,et al.  DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia , 2012, Leukemia.

[4]  B. Ramaswamy,et al.  Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo , 2012, Breast Cancer Research and Treatment.

[5]  Nita Ahuja,et al.  Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. , 2012, Cancer cell.

[6]  Patrick G. Shaw,et al.  Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells , 2012, Breast Cancer Research and Treatment.

[7]  Evelyn Wenkel,et al.  Circulating Micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection , 2012, PloS one.

[8]  C. Zahnow,et al.  OT3-01-06: A Phase 2 Study Investigating the Safety, Efficacy and Surrogate Biomarkers of Response of 5-Azacitidine (5-AZA) and Entinostat (MS-275) in Patients with Advanced Breast Cancer. , 2011 .

[9]  P. Klein,et al.  PD01-04: Entinostat, a Novel Histone Deacetylase Inhibitor, Added to Exemestane Improves PFS in Advanced Breast Cancer in a Randomized, Phase II, Double-Blind Study. , 2011 .

[10]  P. Korkolopoulou,et al.  Association of aberrant DNA methylation with clinicopathological features in breast cancer. , 2011, Oncology reports.

[11]  J. Herman,et al.  Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. , 2011, Cancer discovery.

[12]  M. Ferracin,et al.  MicroRNAs: toward the clinic for breast cancer patients. , 2011, Seminars in oncology.

[13]  Benjamin Haibe-Kains,et al.  DNA methylation profiling reveals a predominant immune component in breast cancers , 2011, EMBO molecular medicine.

[14]  P. Ordentlich.  Abstract PR-6: Pharmacodynamic analysis of ENCORE 301, a placebo-controlled, randomized phase 2 study of exemestane with and without entinostat in postmenopausal ER+ breast cancer patients demonstrates an association of lysine hyperacetylation with clinical outcome. , 2011 .

[15]  Yuan Yao,et al.  Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies. , 2011, Journal of the American Chemical Society.

[16]  Peng Huang,et al.  Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. , 2011, Cancer research.

[17]  J. Scandura,et al.  Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. , 2011, Blood.

[18]  Bolin Liu,et al.  HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance. , 2011, Cancer letters.

[19]  S. Steinberg,et al.  Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. , 2011, Blood.

[20]  M. Moasser,et al.  A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer , 2011, British Journal of Cancer.

[21]  R. Bast,et al.  Phase 1b‐2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum‐resistant or platinum‐refractory epithelial ovarian cancer , 2011, Cancer.

[22]  C. Ricketts,et al.  Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. , 2011, Cancer research.

[23]  S. Sukumar,et al.  Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. , 2011, Cancer research.

[24]  A. Oza,et al.  Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas , 2011, Clinical Cancer Research.

[25]  J. Herman,et al.  BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Becker,et al.  Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Fackler,et al.  Association of vorinostat with decrease in gene expression of proliferation-related genes in tumors from women with newly diagnosed breast cancer. , 2010 .

[28]  H. Dombret,et al.  Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome , 2010, Oncotarget.

[29]  Peter A. Jones,et al.  S110, a 5-Aza-2′-Deoxycytidine–Containing Dinucleotide, Is an Effective DNA Methylation Inhibitor In vivo and Can Reduce Tumor Growth , 2010, Molecular Cancer Therapeutics.

[30]  A. Yang,et al.  Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors. , 2010, Epigenomics.

[31]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[32]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[33]  S. Steinberg,et al.  Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Robert Gray,et al.  Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  P. Munster,et al.  Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker , 2009, British Journal of Cancer.

[36]  Patrick G. Shaw,et al.  Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells , 2009, Breast Cancer Research and Treatment.

[37]  H. Kantarjian,et al.  Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  H. Prince,et al.  Clinical Studies of Histone Deacetylase Inhibitors , 2009, Clinical Cancer Research.

[39]  M. Fackler,et al.  Hypermethylated Genes as Biomarkers of Cancer in Women with Pathologic Nipple Discharge , 2009, Clinical Cancer Research.

[40]  Kristina M Smith,et al.  Genome-wide high throughput analysis of DNA methylation in eukaryotes. , 2009, Methods.

[41]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[42]  A. Munshi,et al.  Histone modifications dictate specific biological readouts. , 2009, Journal of genetics and genomics = Yi chuan xue bao.

[43]  David D. Smith,et al.  A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study , 2008, Clinical Cancer Research.

[44]  T. Yoshizumi,et al.  Expression of Hypoxia-Inducible Factor-1&agr;, Histone Deacetylase 1, and Metastasis-Associated Protein 1 in Pancreatic Carcinoma: Correlation With Poor Prognosis With Possible Regulation , 2008, Pancreas.

[45]  Steven Piantadosi,et al.  DNA methylation markers and early recurrence in stage I lung cancer. , 2008, The New England journal of medicine.

[46]  Jiong Wu,et al.  ERα negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor , 2008, Journal of Cancer Research and Clinical Oncology.

[47]  K. Fabianowska-Majewska,et al.  The Effects of Nucleoside Analogues on Promoter Methylation of Selected Tumor Suppressor Genes in MCF-7 and MDA-MB-231 Breast Cancer Cell Lines , 2007, Nucleosides, nucleotides & nucleic acids.

[48]  P. Kushner,et al.  Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells , 2007, Breast Cancer Research and Treatment.

[49]  T. Kuzel,et al.  Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  J. Issa,et al.  Effect of Cytarabine and Decitabine in Combination in Human Leukemic Cell Lines , 2007, Clinical Cancer Research.

[51]  M. Esteller,et al.  CpG island hypermethylation of tumor suppressor microRNAs in human cancer. , 2007, Cell cycle.

[52]  S. Ramalingam,et al.  Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies , 2007, Clinical Cancer Research.

[53]  M. Esteller.  Cancer epigenomics: DNA methylomes and histone-modification maps , 2007, Nature Reviews Genetics.

[54]  M. Tainsky,et al.  Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2'-deoxycytidine sensitizes human breast cancer cells to adriamycin. , 2007, Cancer research.

[55]  S. Lau,et al.  5-Aza-2′-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation , 2007, Oncogene.

[56]  E Marubini,et al.  Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  M. Grever,et al.  Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. , 2006, Cancer research.

[58]  N. Davidson,et al.  Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. , 2006, Cancer research.

[59]  K. Fabianowska-Majewska,et al.  Alteration of DNA Methylation Status in K562 and MCF-7 Cancer Cell Lines by Nucleoside Analogues , 2006, Nucleosides, nucleotides & nucleic acids.

[60]  H. Yamaguchi,et al.  Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2 , 2005, Clinical Cancer Research.

[61]  L. Schwartz,et al.  Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  K. Ghoshal,et al.  5-Aza-Deoxycytidine Induces Selective Degradation of DNA Methyltransferase 1 by a Proteasomal Pathway That Requires the KEN Box, Bromo-Adjacent Homology Domain, and Nuclear Localization Signal , 2005, Molecular and Cellular Biology.

[63]  H. M. Beier,et al.  Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis , 2005, Breast Cancer Research and Treatment.

[64]  Hiroko Yamashita,et al.  HDAC6 Expression Is Correlated with Better Survival in Breast Cancer , 2004, Clinical Cancer Research.

[65]  Pedram Argani,et al.  Quantitative Multiplex Methylation-Specific PCR Assay for the Detection of Promoter Hypermethylation in Multiple Genes in Breast Cancer , 2004, Cancer Research.

[66]  M. Fackler,et al.  DNA methylation of RASSF1A, HIN‐1, RAR‐β, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma , 2003, International journal of cancer.

[67]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[68]  M. Fackler,et al.  Methylation Profiling of Benign and Malignant Breast Lesions and Its Application to Cytopathology , 2003, Modern Pathology.

[69]  Y. Pommier,et al.  Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. , 2003, Cancer research.

[70]  J. Arts,et al.  Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics. , 2003, Current medicinal chemistry.

[71]  Dipali Sharma,et al.  A Novel Histone Deacetylase Inhibitor, Scriptaid, Enhances Expression of Functional Estrogen Receptor α (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine , 2003, Breast Cancer Research and Treatment.

[72]  P. Atadja,et al.  Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. , 2003, Molecular cancer therapeutics.

[73]  A. Godwin,et al.  Hypomethylation of the Synuclein γ Gene CpG Island Promotes Its Aberrant Expression in Breast Carcinoma and Ovarian Carcinoma , 2003 .

[74]  Rachel Jones,et al.  Behavioural genetics: Worms gang up on bacteria , 2002, Nature Reviews Genetics.

[75]  Martin Widschwendter,et al.  DNA methylation and breast carcinogenesis , 2002, Oncogene.

[76]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[77]  N. Rosen,et al.  The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. , 2001, Cancer research.

[78]  J. Herman,et al.  Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells , 2001 .

[79]  C. Allis,et al.  Translating the Histone Code , 2001, Science.

[80]  M. Grever,et al.  Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[81]  D. Medina,et al.  Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth , 2000, Breast Cancer Research.

[82]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[83]  A. Pardee,et al.  Suberoylanilide Hydroxamic Acid as a Potential Therapeutic Agent for Human Breast Cancer Treatment , 2000, Molecular medicine.

[84]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[85]  P. Marks,et al.  Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). , 1999, Anticancer research.

[86]  D. Haber,et al.  DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development , 1999, Cell.

[87]  S. Weitzman,et al.  Mapping of ER gene CpG island methylation-specific polymerase chain reaction. , 1998, Cancer research.

[88]  A. Weissbach,et al.  Mammalian DNA methyltransferases prefer poly(dI-dC) as substrate. , 1986, The Journal of biological chemistry.

[89]  M. Lippman,et al.  Phase II trial of 13-cis-retinoic acid in metastatic breast cancer. , 1982, European journal of cancer & clinical oncology.

[90]  Peter A. Jones,et al.  Cellular differentiation, cytidine analogs and DNA methylation , 1980, Cell.

[91]  B. Shnider,et al.  A Phase I Study of 5‐Azacytidine (NSC‐102816) , 1976, Journal of clinical pharmacology.

[92]  S. Murphy,et al.  Methylation-specific PCR. , 2013, Methods in molecular biology.

[93]  S. Galbavy,et al.  RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer. , 2011, Cancer biomarkers : section A of Disease markers.

[94]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[95]  A. Godwin,et al.  Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. , 2003, Cancer research.

[96]  J. Herman,et al.  Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. , 2001, Cancer research.

[97]  M. Cravo,et al.  Global DNA hypomethylation in breast carcinoma , 1999, Cancer.

[98]  S. Weitzman,et al.  Mapping of ER gene CpG island methylation-specific polymerase chain reaction. , 1998, Cancer research.

[99]  S. Moss,et al.  Phase II study of 5-azacytidine in solid tumors. , 1977, Cancer treatment reports.